In addition, we will consider other KRAS-mutant cancers, such as CRAC and LUAC, and compare them with PDAC, aiming to uncover the mechanism by which KRAS mutation dictates the cancer immune status across these adenocarcinomas. This evidence concerns the gene KRAS and adenocarcinoma.